SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older. ...continue reading
View reconstitution instructions for
A brief review of the key elements from the pivotal clinical trials.
|*||Data from the phase 3 ZOE-50 (≥50 years of age) trial and pooled data in individuals ≥70 years of age from the phase 3 ZOE-70 and ZOE-50 trials from subjects randomized to receive 2 doses of SHINGRIX (N=7698 and 8250, respectively) or placebo (N=7713 and 8346, respectively). See study designs on Efficacy page for details.1,2
References: 1. Prescribing Information for SHINGRIX. 2. Lal H, Cunningham AL, Godeaux O, et al, for the ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087-2096.
All trademarks are the property of their respective owners.
1008012R0 August 2018